CLINICAL TRIAL SUMMARY

MDACC Study No:2010-0727 (clinicaltrials.gov NCT No: NCT01303796)
Title:A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia
Principal Investigator:Hagop Kantarjian
Treatment Agent:Cytarabine; Decitabine; Sapacitabine
Study Status:Open
Study Description:The goal of this clinical research study is to compare the ability of
decitabine given alone versus the combination of sapacitabine and decitabine to
control AML. The safety of the drug combination will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase III
Treatment Agents:Cytarabine
Decitabine
Sapacitabine
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Cyclacel Ltd.
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Hagop Kantarjian
Dept:Leukemia
For Clinical Trial Enrollment:713-792-7026
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults